Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Schanza, LM; Seles, M; Stotz, M; Fosselteder, J; Hutterer, GC; Pichler, M; Stiegelbauer, V.
MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Int J Mol Sci. 2017; 18(11): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Foßelteder Johannes
Hutterer Georg C.
Pichler Martin
Seles Maximilian
Stiegelbauer Verena
Stotz Michael
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Number of Figures: 2
| |
Abstract:
Renal cell carcinoma (RCC) are the most common renal neoplasia and can be divided into three main histologic subtypes, among which clear cell RCC is by far the most common form of kidney cancer. Despite substantial advances over the last decade in the understanding of RCC biology, surgical treatments, and targeted and immuno-therapies in the metastatic setting, the prognosis for advanced RCC patients remains poor. One of the major problems with RCC treatment strategies is inherent or acquired resistance towards therapeutic agents over time. The discovery of microRNAs (miRNAs), a class of small, non-coding, single-stranded RNAs that play a crucial role in post-transcriptional regulation, has added new dimensions to the development of novel diagnostic and treatment tools. Because of an association between Von Hippel-Lindau (VHL) genes with chromosomal loss in 3p25-26 and clear cell RCC, miRNAs have attracted considerable scientific interest over the last years. The loss of VHL function leads to constitutional activation of the hypoxia inducible factor (HIF) pathway and to consequent expression of numerous angiogenic and carcinogenic factors. Since miRNAs represent key players of carcinogenesis, tumor cell invasion, angiogenesis, as well as in development of metastases in RCC, they might serve as potential therapeutic targets. Several miRNAs are already known to be dysregulated in RCC and have been linked to biological processes involved in tumor angiogenesis and response to anti-cancer therapies. This review summarizes the role of different miRNAs in RCC angiogenesis and their association with the VHL gene, highlighting their potential role as novel drug targets.
Find related publications in this database (using NLM MeSH Indexing)
Angiogenesis Inhibitors - pharmacology
Angiogenesis Inhibitors - therapeutic use
Animals -
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - genetics
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - pathology
Gene Expression Regulation, Neoplastic - drug effects
Humans -
Hypoxia-Inducible Factor 1 - metabolism
Kidney Neoplasms - drug therapy
Kidney Neoplasms - genetics
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
MicroRNAs - genetics
Molecular Targeted Therapy -
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - genetics
Neovascularization, Pathologic - metabolism
Signal Transduction -
Von Hippel-Lindau Tumor Suppressor Protein - metabolism

Find related publications in this database (Keywords)
renal cell carcinoma
Von Hippel-Lindau
angiogenesis
microRNAs
© Med Uni Graz Impressum